Nebraska will receive nearly $5 million from Abbott Laboratories to settle concerns that it improperly marketed its anti-seizure drug Depakote.
Nebraska Attorney General Jon Bruning says the state will receive a share of the $1.5 billion settlement Abbott agreed to.
Nebraska's Medicaid program will receive $3.7 million, and $1.2 million will go to the state's consumer settlement fund.
Depakote is an anti-seizure and mood-stabilizing drug that's prescribed for bipolar disorder. Abbott admitted marketing Depakote for unapproved uses including dementia and schizophrenia in violation of FDA rules.
The national settlement was announced Monday.
Viewers with disabilities can get assistance accessing this station's FCC Public Inspection File by contacting the station with the information listed below. Questions or concerns relating to the accessibility of the FCC's online public file system should be directed to the FCC at 888-225-5322, 888-835-5322 (TTY), or email@example.com.